Investor Relations

Investor Relations

We are a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

Stock Chart

Events & Presentations

Date Title
05/22/18 at
4:00 PM EDT
UBS Global Healthcare Conference
04/09/18 at
11:55 AM CEST
H.C. Wainwright Global Life Sciences Conference
Print Page
Email Page
Contact IR
Email Alerts
Tear Sheet